3,208 Shares in Solventum Co. (NYSE:SOLV) Bought by denkapparat Operations GmbH

denkapparat Operations GmbH acquired a new stake in Solventum Co. (NYSE:SOLV) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,208 shares of the company’s stock, valued at approximately $212,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Worldquant Millennium Advisors LLC grew its position in shares of Solventum by 373.6% in the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock valued at $3,323,000 after purchasing an additional 37,600 shares during the period. Harbor Capital Advisors Inc. grew its stake in Solventum by 24.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after acquiring an additional 9,333 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Solventum by 37.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after purchasing an additional 32,051 shares in the last quarter. State Street Corp boosted its holdings in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Finally, Forsta AP Fonden purchased a new stake in shares of Solventum in the fourth quarter valued at approximately $1,876,000.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SOLV. Wells Fargo & Company boosted their price objective on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th. Piper Sandler lifted their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Bank of America increased their price target on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Finally, Mizuho lifted their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.86.

Solventum Trading Down 1.0 %

SOLV opened at $74.78 on Friday. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business has a fifty day simple moving average of $75.51 and a 200-day simple moving average of $71.83. The firm has a market cap of $12.94 billion and a P/E ratio of 27.19.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.